Univ.-Prof. Dr. Werner Scheithauer

Univ.-Prof. Dr. Werner Scheithauer

Programmdirektionen: Kolorektal-, Pankreas-, Gallenwegskarzinom, Lebertumore
Promotion: 10.07.1981
Facharztdatum: 16.12.1987
Habilitationsdatum: 29.06.1990
Additivfächer: Hämato-Onkologie, Gastroenterolgie & Hepatologie
Forschungsschwerpunkte: Kolorektal-, Pankreas-, Gallenwegskarzinom, Lebertumoren, klinische Studien
Publikationen: Pub-Med Publikationsservice
227 Originalarbeiten,
> 60 Buchbeiträge/Reviews,
> 450 Abstrakts

Positionen:
- Konsiliaronkologe im Landesklinikum Wr.Neustadt und LKH Neunkirchen

- Councillor der European Society for Clinical Investigation (ESCI): 1988-91

- Member of the Global Associates of the Institute for Drug Development of the Cancer Therapy & Research Center in Texas (seit 94)

- Vorstandsmitglied der (1) Österr. Gesellschaft für Hämatologie & Onkologie (ÖGHO; seit 96), (2) Society for Investigation of the Biology & Treatment of Cancer (seit 96) und (3) Austrian Society for Applied Pharmacokinetics (seit 01)

- Member of the scientific advisory board of the European Multidisciplinary Conference Group on Colorectal Cancer

- Member of the Faculty of the European Society for Medical Oncology for Gastrointestinal Tumors (seit 06)

- Contributing Member of the Oncology Agents Section in the ‘FACULTY OF 1000′ (www.f1000.com) (since 11)

- Member of the Editorial Boards of
(1) Annals of Oncology, (seit 06),
(2) Onkologie – Int.Journal for Cancer Research and Treatment (seit 99),
(3) Journal for Gastroenterological and Hepatological Disorders (seit 08) und
(4) Chemotherapy Research and Practice (seit 09) und (5) Journal of Solid Tumors (seit 2011)

- Mitglied des Wissenschaftsbeirates der (1) Fellinger Stiftung und (2) des Theodor-Billroth- & Erste-Bank Preis-Komittees der Ärztekammer


Auszeichnungen:
- Österreichischer Staatspreis für Rheumatolgie 1987- Wolfgang Denk Preis der ÖGHO 1994- Outstanding Manuscript Award for Human Studies of the Journal of Nuclear Medicine 1995- Mallinckrodt Award of the Austrian Society for Nuclear Medicine 1996- Bristol-Myers Squibb Price of the Austrian Society for Internal Medicine 1997

- Best Poster Award at the 27 th Congress of the European Society for Medical Oncolgy 2002

- “Eminent Scientist of the year 2005 Award – Europe” in Medical Oncology of the International Research Promotion Council (IRPC)


Grants:
-  Jubiläumsfond der österreichischen National Bank, Projekt #2143 “Individualized chemotherapeutic treatment of malignant tumors of the digestive tract”, 1983-85

-  Fonds zur Förderung der Wissenschaftlichen Forschung, Projekt #P-5352 “tumor-specific optimization of the human tumor stem cell assay for GI malignancies”, 1984-86

-  Erwin Schrödinger Stipendium, Projekt #J-0024 “Preclinical and clinical studies on the development of new anticancer drugs”, 1984-85

-  Kommission Onkologie-Krebsforschung der MUW, Project “PH-dependency of in vitro chemosensitivity and modulation of drug resistance”, 93-95

-  Jubliläumsfonds der österreichischen National Bank, Projekt #6587″ “Role of peptides for growth inhibition of pancreatic cancer”, 1997-98

-  Med.Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien, 1998

Publikationen der letzten 3 Jahre:
1.  André T, Reyes-Vidal JM, Fartoux L, Ross P, Leslie M, Rosmorduc O, Clemens MR, Louvet C, Perez N, Mehmud F, Scheithauer W . Gemcitabine and oxaliplatin in advanced biliary tract carcinoma: a phase II study. Br J Cancer. 2008 Sep 16;99(6):862-7.

2.  Bernhard J, Dietrich D, Scheithauer W , Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D, Herrmann R; Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial–SAKK 44/00-CECOG/PAN.1.3.001. J Clin Oncol. 2008 Aug 1;26(22):3695-701.

3.  Van Cutsem E, Dicato M, Haustermans K, Arber N, Bosset JF, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Goldberg R, Glynne-Jones R, Haller D, Kang YK, Kerr D, Labianca R, Minsky BD, Moore M, Nordlinger B, Rougier P, Scheithauer W , Schmoll HJ, Sobrero A, Tabernero J, Tempero M, Van de Velde C, Zalcberg J. The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. Ann Oncol. 2008 Jun;19 Suppl 6:vi1-8.

4.  Gruenberger B, Scheithauer W , Punzengruber R, Zielinski C, Tamandl D, Gruenberger T: Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer. 2008 Apr 25;8:120.

5.  Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W , Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008 Apr 20;26(12):2013-9.

6.  Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W , Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Saltz L. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008 Apr 20;26(12):2006-12.

7.  Gruenberger B, Tamandl D, Schueller J, Scheithauer W , Zielinski C, Herbst F, Gruenberger T. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol. 2008 Apr 10;26(11):1830-5.

8.  Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W , Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G, Kröning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit J, Burris HA 3rd. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008 May 10;26(14):2311-9.

9.  Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W , Gruenberger T; EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO); Australasian Gastro-Intestinal Trials Group (AGITG); Fédération Francophone de Cancérologie Digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet. 2008 Mar 22;371(9617):1007-16.

10.  Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W , Herrmann R. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008 Feb;9(2):132-8.

11.  Van Cutsem E, Siena S, Humblet Y, Canon JL, Maurel J, Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer W , Spadafora S, Amado RG, Hogan N, Peeters M. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol. 2008 Jan;19(1):92-8.

12.  Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009 Nov 20;27(33):5513-8

13.  Vormittag L, Gleiss A, Scheithauer W , Lang F, Laengle F, Kornek GV. Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer. Oncology. 2009;77(2):140-6.

14.  Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, Quirke P, Schmoll HJ, Sebag-Montefiore D, Taylor I, Van Cutsem E, Van de Velde C, Cellini N, Latini P: Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol. 2009 Aug;92(2):148-63.

15.  Scheithauer W , Schmiegel W. Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer. Onkologie. 2009 Jul;32(7):431-9

16.  Verslype C, Van Cutsem E, Dicato M, Arber N, Berlin JD, Cunningham D, De Gramont A, Diaz-Rubio E, Ducreux M, Gruenberger T, Haller D, Haustermans K, Hoff P, Kerr D, Labianca R, Moore M, Nordlinger B, Ohtsu A, Rougier P, Scheithauer W , Schmoll HJ, Sobrero A, Tabernero J, van de Velde C. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008. Ann Oncol. 2009 Jun;20 Suppl 7:vii1-vii6.

17  Van Cutsem E, Vervenne WL, Bennouna J, Humblet Y, Gill S, Van Laethem JL, Verslype C, Scheithauer W , Shang A, Cosaert J, Moore MJ. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009 May 1;27(13):2231-7.

18.   Winder T, Scheithauer W, Lang A. K-ras mutations and cetuximab in colorectal cancer. N Engl J Med. 2009 Feb 19;360(8):834-5; author reply 835-6.

19.   Ocvirk J, Brodowicz T, Wrba F, Ciuleanu TE, Kurteva G, Beslija S, Koza I, Pápai Z, Messinger D, Yilmaz U, Faluhelyi Z, Yalcin S, Papamichael D, Wenczl M, Mrsic-Krmpotic Z, Shacham-Shmueli E, Vrbanec D, Esser R, Scheithauer W, Zielinski CC. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol . 2010 Jul 7;16(25):3133-43.

20.   Farkouh A, Schueller J, Scheithauer W, Czejka M. Plasma disposition of capecitabine (CCB) and its metabolites 5′-deoxy-5-fluorocytidine (5′-DFCR) and 5′-deoxy-5-fluorouracil (5′-DFUR) with two different capecitabine/oxaliplatin dosage regimens Int J Clin Pharmacol Ther . 2010 Jul;48(7):487-8

21.   Czejka M, Schueller J, Farkouh A, Gruenberger B, Scheithauer W. Plasma disposition of capecitabine and its metabolites 5′DFCR and 5′DFUR in a standard and dose-intensified monotherapy regimen. Cancer Chemother Pharmacol . 2010 May 22.

22. Bernhard J, Dietrich D, Glimelius B, Hess V, Bodoky G, Scheithauer W, Herrmann R Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer . 2010 Oct 26;103(9):1318-24

23. Scheithauer W . Chemotherapy: Gemcitabine alone or plus cisplatin for biliary tract cancer? Nat Rev Clin Oncol . 2010 Oct;7(10):554-5

24. Farkouh A, Ettlinger D, Schueller J, Georgopoulos A, Scheithauer W, Czejka M . A rapid and simple HPLC assay for quantification of capecitabine for drug monitoring purposes. Anticancer Res . 2010 Dec;30(12):5207-11

25. Resch G, Schaberl-Moser R, Kier P, Kopetzky G, Scheithauer W, Sliwa T, Greil R, Nösslinger T, Mayrbäurl B, Thaler J . Infusion reactions to the chimeric EGFR inhibitor cetuximab–change to the fully human anti-EGFR monoclonal antibody panitumumab is safe. Ann Oncol . 2011 Feb;22(2):486-7

26. Kanz R, Vukovich T, Vormittag R, Dunkler D, Ay C, Thaler J, Haselböck J, Scheithauer W, Zielinski C, Pabinger I. Thrombosis risk and survival in cancer patients with elevated C-reactive protein. J Thromb Haemost . 2011 Jan;9(1):57-63

27. Cassidy J, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Rittweger K, Gilberg F, Saltz L. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer . 2011 Jun 28;105(1):58-64.

Seitenleiste